ClinicalTrials.gg
CompletedNCT04203797Updated Apr 18, 2024Results posted

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

A Phase 4 interventional study of dupilumab and Matching placebo in Asthma, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in 5 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
25th of 31
40 · median 120
Started
2020
with 3 others
Phase 4
14 of 31
5 open now
Registered
14th of 31
by date
Lead sponsor
3 of 31
Regeneron Pharmaceuticals

Among the 31 studies testing dupilumab in Asthma, this one is the 25th largest by enrollment, is one of 4 that started in 2020, is one of 14 in phase 4, and was the 14th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.

The secondary objectives of the study are:

  • To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma
  • To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma
03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • A physician diagnosis of asthma
  • Pre-bronchodilator between 30% and 75% predicted at both the screening and baseline visits
  • Bronchodilator reversibility defined as >200 mL and 12% increase in FEV1 post-administration of a short-acting beta agonist (SABA). A patient may also qualify if there is a documented history of bronchodilator reversibility or positive methacholine challenge test within 12 months prior to the screening visit
  • Stable background therapy for at least 3 months with a stable dose ≥4 weeks prior to the baseline visit of a medium-to-high dose ICS (fluticasone propionate ≥250 to 1000 μg twice daily [BID] or equivalent) in combination with at least a second controller medication (eg, long-acting beta agonist [LABA], long-acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA], theophylline, etc.); a third controller is allowed and with the same stabilization requirements
  • Blood eosinophil count ≥300 cells/μL for patients not on maintenance OCS at the screening visit
  • ACQ-5 score ≥1.5 at the screening and baseline visits

Key Exclusion Criteria:

  • >35 kg/m2 at screening
  • Current smoking, vaping or tobacco chewing or cessation of any of these within 6 months prior to randomization, or >10 pack years smoking history
  • Patients who require supplemental oxygen at screening
  • cardiac disease as described in the protocol
  • Uncontrolled hypertension at screening or baseline
  • Participation in exercise or physical rehabilitation program within last 6 months prior to screening or planned during the study
  • Previous use of dupilumab
  • Anti-IgE therapy (eg, omalizumab [Xolair®]) within 130 days prior to visit 1 or any other biologic therapy (including anti-IL5, anti-IL-5R, anti-IL4Rα, anti-IL-13 mAb) or systemic (eg, methotrexate, any anti-tumor necrosis factor mAbs, Janus kinase inhibitors, B- and/or T-cell targeted immunosuppressive therapies) to treat inflammatory disease or disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 3 months or 5 half-lives prior to screening, whichever is longer
  • Exposure to another investigative drug (monoclonal antibodies as well as small molecules) within a period prior to screening, of \<3 months or \<5 half-lives (whichever is longer)
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
  • Women of (WOCBP)* who are unwilling to practice highly effective prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    dupilumab

    A loading dose at the start of the treatment followed by once every two weeks (Q2W).

    Drug: dupilumab

  • Experimental
    Matching placebo

    Matching dupilumab

    Drug: Matching placebo

Interventions

  • Pre-filled syringe administered by subcutaneous (SC) injections

    Also known as: Dupixent®, SAR231893

  • DrugMatching placebo

    Pre-filled syringe administered by subcutaneous (SC)

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)

    CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.

    Time frame: Up to week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Average Number of Steps Walked Per Day

    Based on accelerometry data

    Time frame: Up to week 12

  2. Change From Baseline to Week 12 in Total Energy Expenditure

    Metabolic equivalents of tasks \[METs\]. Based on accelerometry data

    Time frame: Up to week 12

  3. Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity

    Defined as ≥3 METs. Based on accelerometry data

    Time frame: Up to week 12

  4. Change From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)

    Based on spirometry data

    Time frame: Up to week 12

07

Results

Posted Apr 18, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboDupilumab
Started2020
Completed1820
Not completed20
Withdrew: Adverse event10
Withdrew: Did not complete end of study follow-up10

Outcome measures

PrimaryChange From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)

CWRET (Constant Work Rate Exercise Test) will be performed on an electromagnetically-braked cycle ergometer in an exercise physiology laboratory overseen by a trained pulmonologist or medical doctor designee.

Time frame:
Up to week 12
Reported as:
Mean · Minutes
Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)
MinutesPlaceboDupilumab
Change From Baseline to Week 12 in Constant Work Rate Exercise Endurance Time - CWRET (Constant Work Rate Exercise Test)0.923 (-0.614 to 2.460)1.742 (-0.054 to 3.538)
SecondaryChange From Baseline to Week 12 in Average Number of Steps Walked Per Day

Based on accelerometry data

Time frame:
Up to week 12
Reported as:
Mean · Steps
Change From Baseline to Week 12 in Average Number of Steps Walked Per Day
StepsPlaceboDupilumab
Change From Baseline to Week 12 in Average Number of Steps Walked Per Day-1066.11 (-2921.32 to 789.10)925.92 (-691.46 to 2543.30)
SecondaryChange From Baseline to Week 12 in Total Energy Expenditure

Metabolic equivalents of tasks \[METs\]. Based on accelerometry data

Time frame:
Up to week 12
Reported as:
Mean · METs (metabolic equivalent of task)
Change From Baseline to Week 12 in Total Energy Expenditure
METs (metabolic equivalent of task)PlaceboDupilumab
Change From Baseline to Week 12 in Total Energy Expenditure23.40 (-87.37 to 134.17)59.36 (-15.83 to 134.55)
SecondaryChange From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity

Defined as ≥3 METs. Based on accelerometry data

Time frame:
Up to week 12
Reported as:
Mean · Minutes
Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity
MinutesPlaceboDupilumab
Change From Baseline to Week 12 in the Mean Duration of Moderate-to-vigorous Physical Activity-11.01 (-30.52 to 8.50)9.38 (-13.41 to 32.18)
SecondaryChange From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)

Based on spirometry data

Time frame:
Up to week 12
Reported as:
Mean · Liters
Change From Baseline to Week 12 in Pre- and Post-exercise Forced Expiratory Volume in One Second (FEV1)
LitersPlaceboDupilumab
Change from Baseline to Week 12 (Pre-exercise)0.2123 (0.0072 to 0.4174)0.4205 (0.1409 to 0.7000)
Change from Baseline to Week 12 (2-min Post-Exercise)0.2550 (-0.2390 to 0.7490)0.2902 (0.0886 to 0.4919)
Change from Baseline to Week 12 (5-min Post-Exercise)0.2416 (0.0238 to 0.4593)0.4156 (0.1505 to 0.6808)
Change from Baseline to Week 12 (10-min Post-Exercise)0.2211 (0.0180 to 0.4243)0.4613 (0.2167 to 0.7060)
Change from Baseline to Week 12 (20-min Post-Exercise)0.2496 (0.0608 to 0.4384)0.4738 (0.2230 to 0.7245)

Adverse events

Collected over Up to 22 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/20 (0%)0/20 (0%)9/20 (45%)
Dupilumab 300 mg Q2W0/20 (0%)0/20 (0%)3/20 (15%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboDupilumab 300 mg Q2W
COVID-19Infections and infestations3/200/20
AsthmaRespiratory, thoracic and mediastinal disorders2/201/20
HeadacheNervous system disorders2/200/20
CoughRespiratory, thoracic and mediastinal disorders1/201/20
Sinus painRespiratory, thoracic and mediastinal disorders0/201/20
Injection site erythemaGeneral disorders0/201/20
RhinitisInfections and infestations0/201/20
BronchitisInfections and infestations1/200/20
Respiratory tract infectionInfections and infestations1/200/20
Immunisation reactionInjury, poisoning and procedural complications0/201/20

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDupilumabTotal
Mean46.5 ± 7.745.3 ± 7.845.9 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDupilumabTotal
Female11819
Male91221
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDupilumabTotal
Hispanic or Latino123
Not Hispanic or Latino191837
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboDupilumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American213
White181937
More than one race000
Unknown or Not Reported000
08

Study locations

30 sites
  • Palos Verdes Medical Group (PVMG); Peninsula Research Associates (PRA)
    Rolling Hills Estates, California 90274, United States
  • UCLA Medical Center - Harbor
    Torrance, California 90509, United States
  • Allianz Research Institute
    Westminster, California 92683, United States
  • University of Iowa Hospitals & Clinics-Roy J. and Lucille A. Carver College of Medicine
    Iowa City, Iowa 52242, United States
  • University Of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Infinity Medical Research
    North Dartmouth, Massachusetts 02747, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • American Health Research
    Charlotte, North Carolina 28277, United States
  • UH Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Regeneron Study Site
    Hendersonville, Tennessee 37075, United States
  • The University of Texas Medical School at Houston
    Houston, Texas 77030, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • CHU Dijon
    Dijon, Bourgogne 21000, France
  • CHU Reims
    Reims, Marne 51092, France
  • CHU de Strasbourg - Nouvel Hopital Civil
    Strasbourg, 67091, France
  • Praxis Dr. M. Rolke u. Dr. P. Rueckert
    Aschaffenburg, Bavaria 63739, Germany
  • Regeneron Study Site
    Frankfurt am Main, Hessen 60389, Germany
  • IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG.
    Frankfurt am Main, Hessen 60596, Germany
  • Regeneron Study Site
    Hannover, Lower Saxony 30625, Germany
  • Regeneron Study Site
    Koblenz, Rheinland-Pfalz 56068, Germany
  • IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz
    Mainz, Rheinland-Pfalz 55128, Germany
  • Regeneron Study Site
    Grosshansdorf, Schleswig-Holstein 22977, Germany
  • KLB - Gesundheitsforschung Luebeck GmbH
    Luebeck, Schleswig-Holstein 486344, Germany
  • Regeneron Study Site
    Berlin, 12159, Germany
  • Regeneron Study Site
    Lubin, Dolnoslaskie 59-300, Poland
  • Centrum Medycyny Oddechowej, Mroz Spolka Jawna
    Bialystok, 15-044, Poland
  • Lekarze Specjalisci - J. Malolepszy i Partnerzy
    Wroclaw, 54-239, Poland
  • Hospital Universitario de Bellvitge
    Barcelona, 08907, Spain
  • Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM)
    Madrid, 28007, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jul 2023, 35 months.

Results were first posted in Apr 2024, 9 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 35 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Dec 18, 2019
StartActual
Jul 16, 2020
Primary completionActual
Jul 15, 2023
CompletionActual
Jul 15, 2023
Results first posted
Apr 18, 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04203797
Responsible party
Sponsor
First posted
Dec 18, 2019
Start date
Jul 16, 2020
Primary completion
Jul 15, 2023
Completion
Jul 15, 2023
Results posted
Apr 18, 2024
Last update
Apr 18, 2024

Study contacts

Clinical Trials Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion